Phase I/II NabPaclitaxel, Paclitaxel&Carboplatin w RTX Followed by Consolidation in
Patients w Favorable Prognosis Inoperable Stage IIIA/B NSCLC
Does the drug paclitaxel help treat patients with non-small cell lung cancer?
Basic Study Information
Purpose:Location: University of Rochester
The investigators propose this phase I/II study to use weekly Nab-Paclitaxel (Abraxane)
carboplatin with concurrent radiation in local-regionally advanced lung cancer. There
published human studies combining Nab-Paclitaxel (Abraxane) with radiation. The investigators
will first confirm the tolerated dose (TD) of concurrent Nab-Paclitaxel (Abraxane)
50mg/m2, and then will begin enrolling patients into the phase II component using
Nab-Paclitaxel (Abraxane) at the TD with carboplatin concurrent with daily radiation
paclitaxel with with carboplatin concurrent with daily radiation.
Lead Researcher (Principal Investigator)
Lead Researcher: Yuhchyau Chen
Study Contact InformationStudy Coordinator: Yuhchyau Chen, MD
Phone: (585) 275-2171
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search